Thomas Catinazzo - Jan 27, 2022 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
Chief Financial Officer
Signature
/s/ Brian Adams, as Attorney-in-Fact
Stock symbol
RLAY
Transactions as of
Jan 27, 2022
Transactions value $
$0
Form type
4
Date filed
1/31/2022, 04:21 PM
Previous filing
Dec 27, 2021
Next filing
Mar 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Award $0 +39.3K +261.99% $0.00 54.3K Jan 27, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLAY Stock Option (Right to Buy) Award $0 +78.5K $0.00 78.5K Jan 27, 2022 Common Stock 78.5K $20.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. The RSUs shall vest in sixteen (16) equal quarterly installments commencing on January 27, 2022, subject to the reporting person's continued service with the Issuer through each vesting date.
F2 Includes 52,165 shares underlying RSUs.
F3 The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 27, 2022, subject to the reporting person's continued service with the Issuer through each vesting date.